Calliditas gets additional seven-year orphan drug exclusivity for Tarpeyo

Shares of Sweden-headquartered Calliditas Therapeutics (Nasdaq Stockholm: CALT) were up 6.8% at 116.60 kronor by mid-morning after revealing a patent extension on its lead product.

Calliditas said that the US Food and Drug Administration (FDA) has granted an orphan exclusivity period of seven years for Tarpeyo (budesonide), expiring in December 2030, based on the company obtaining full approval with a new indication for this product.

Following full approval…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.• Daily roundup of key events in pharma and biotech.• Monthly in-depth briefings on Boardroom appointments and M&A news.• Choose from a cost-effective annual package or a flexible monthly subscription.